Pancreatic Cancer Research

Clinical trialPhase 2Completed

MDX-010 in Treating Patients With Stage IV Pancreatic Cancer That Cannot Be Removed By Surgery

Phase II Trial of Single Agent Ipilimumab (MDX-010 Anti CTLA-4) for Subjects With Locally Advanced or Metastatic Pancreatic Adenocarcinoma

NCT00112580↗ ClinicalTrials.gov, retrieved 4 November 2026

Outcome
Outcome unknown
Phase
Phase 2
Status
Completed
Study type
Interventional
Start
31 July 2005
Expected end
30 June 2009
Enrollment
27 participants
Sites
2
Primary outcomes
Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR)
Sponsor
Industry
Results posted
2021-09-27
Last update
27 September 2021

These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.

Try

Papers 1

The registry lists these as results papers; in a hand check of 27 such links about 78% reported the trial’s results, so read the paper before treating it as the outcome.